Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov Sells 40,584 Shares of Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENCGet Free Report) CEO Rosty Raykov sold 40,584 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $10.78, for a total transaction of $437,495.52. Following the transaction, the chief executive officer now directly owns 276,054 shares in the company, valued at $2,975,862.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Fennec Pharmaceuticals Stock Performance

Shares of NASDAQ:FENC opened at $10.77 on Thursday. The stock has a market capitalization of $291.22 million, a price-to-earnings ratio of -17.66 and a beta of 0.38. Fennec Pharmaceuticals Inc has a 1-year low of $6.30 and a 1-year high of $11.92. The company’s fifty day moving average is $9.99 and its two-hundred day moving average is $9.10.

Institutional Trading of Fennec Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Fennec Pharmaceuticals by 1,294.3% during the 4th quarter. Vanguard Group Inc. now owns 1,140,063 shares of the company’s stock valued at $12,792,000 after buying an additional 1,058,295 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Fennec Pharmaceuticals by 78.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 31,000 shares of the company’s stock valued at $348,000 after purchasing an additional 13,664 shares in the last quarter. Barclays PLC boosted its position in shares of Fennec Pharmaceuticals by 624.7% during the 4th quarter. Barclays PLC now owns 25,075 shares of the company’s stock valued at $282,000 after purchasing an additional 21,615 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Fennec Pharmaceuticals by 21.1% during the 4th quarter. Royal Bank of Canada now owns 7,102 shares of the company’s stock valued at $79,000 after purchasing an additional 1,236 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Fennec Pharmaceuticals by 107.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock valued at $34,000 after purchasing an additional 1,578 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Wedbush restated an “outperform” rating and issued a $16.00 target price on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th. Craig Hallum upped their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, March 18th.

Read Our Latest Report on FENC

Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

See Also

Insider Buying and Selling by Quarter for Fennec Pharmaceuticals (NASDAQ:FENC)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.